Top in endocrinology: FDA warns about noninvasive glucose readings; diabetes in children

The FDA issued a warning to people with diabetes not to use smartwatches or smart rings that do not pierce the skin for measuring blood glucose because the readings could be inaccurate.

Further, the FDA has not authorized any smartwatch or smart ring for measuring glucose.

Any person who has experienced an adverse event related to inaccurate blood glucose measurement from a smartwatch or smart ring is encouraged to report it through the FDA MedWatch Voluntary Reporting Form.

It was the top story in endocrinology last week.

In another top story, a study based in Scotland found new-onset type 1 diabetes rates among children declined in 2022 to pre-pandemic levels following a significant increase in 2021. The highest incidence of new cases from 2015 to 2022 occurred in children ages 6 to 14 years.

Read these and more top stories in endocrinology below:

FDA: Avoid using smartwatches, smart rings to measure blood glucose

The FDA is warning people with diabetes and the public that noninvasive smartwatches or smart rings that do not pierce the skin should not be used to measure blood glucose, according to a press release. Read more.

New-onset type 1 diabetes cases among children decline in 2022 after sharp increase

Rates of new-onset type 1 diabetes among children fell back to pre-pandemic levels in 2022 after sharply increasing in 2021, according to a population-wide analysis of data from Scotland published in Diabetes Care. Read more.

CATALYST: Hypercortisolism prevalence high with difficult-to-treat type 2 diabetes

Hypercortisolism is prevalent among nearly one-quarter of people with difficult-to-control type 2 diabetes enrolled in a prospective phase 4 study, according to an industry press release. Read more.

Surgical remission of Cushing’s disease may increase odds for autoimmune disease

Adults who achieved remission after surgery for Cushing’s disease are more likely to develop autoimmune disease than those with nonfunctioning pituitary adenomas, according to data published in Annals of Internal Medicine. Read more.

Investigational monthly obesity drug led to durable weight loss in phase 1 trial

Adults with obesity who received an injectable GIP receptor antagonist/GLP-1 receptor agonist every 4 weeks had a decrease in body weight that was maintained for up to 150 days, according to study findings published in Nature Metabolism. Read more.